Larvol Delta - Improvement-in-the-Axial-Domain-With-Deucravacitinib-Through-Week-52-in-Patients-With-PsA-and-Axial-Involvement-2-Randomized-Controlled-Phase-3-Trials

Saphnelo (anifrolumab-fnia) - AstraZeneca

https://acrconvergence2026.eventscribe.net/fsPopup.asp?PresentationID=1899438&mode=presInfo

Jennifer Rogers, MD

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next